Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

PURPOSE Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic value of circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes. METHODS Lymphoma-specific variable,...

  • Monitoring ctDNA can predict relapse after CAR-T for DLBCL, especially when post treatment PET may be unequivocal.